No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
IOL Chemicals and Pharmaceuticals Limited is a global manufacturer and supplier of a diverse range of pharmaceutical and chemical products. The company’s pharmaceutical portfolio focuses on Active Pharmaceutical Ingredients (APIs), providing essential compounds such as ibuprofen lysinate and ibuprofen sodium, alongside a variety of other APIs like metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole, gabapentin, levetiracetam, and paracetamol. These APIs are utilized in medications designed for treatments spanning anti-inflammatory, analgesic, antipyretic, anti-diabetic, anti-platelet, anti-cholesterol, anti-convulsant, and anti-cholelithic purposes, as well as proton pump inhibition. Additionally, IOL offers specialty industrial chemicals, including ethyl acetate, iso butyl benzene, acetyl chloride, para amino phenol, and mono chloro acetic acid. These chemicals cater to a broad spectrum of industries, including food processing, flexible packaging, textiles, ink and paint production, pesticide manufacturing, and other chemical intermediate applications. Incorporated in 1986, IOL Chemicals and Pharmaceuticals Limited is based in Ludhiana, India.
www.iolcp.comNo one on the platform currently holds IOLCP.BO.
No tracked institution reports a position in IOLCP.BO as of their last filing.
No one on the platform has traded IOLCP.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.5% | 7.9% | 16.6% | — | — | — |
| Rev. Growth % | 12.1% | 3.6% | ||||
| Profit Margin % | 5.9% | 6.2% | 9.1% | |||
| Free Cash Flow Margin % | 1.7% | -1.2% | 5.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $27.4B | +19.1% | $7.50 | $7.50–$7.50 | — | 1 |
| 2028 | $31.5B | +15.0% | $9.70 | $9.70–$9.70 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| IOLCP.BOIOL Chemicals and Pharmaceuticals Limited | $179.45 | -7.26% | $52.7B | — |
| ALEMBICLTD.NSAlembic Limited | $100.51 | -3.66% | $25.8B | — |
| HIKAL.BOHikal Limited | $212.35 | -6.47% | $26.1B | — |
| HIKAL.NSHikal Limited | $212.22 | -5.66% | $26.2B | — |
| INDOCO.NSIndoco Remedies Limited | $241.39 | -8.22% | $22.2B | — |
| MOREPENLAB.BOMorepen Laboratories Limited | $106.25 | -8.37% | $58.3B | — |
| MOREPENLAB.NSMorepen Laboratories Limited | $106.22 | -8.26% | $58.2B | — |
Source: Financial Modeling Prep · peers by sector/industry